Primrose Bio and Intravacc Collaborate for the Development of Conjugate Vaccine

Share this

Primrose Bio and Intravacc Collaborate for the Development of Conjugate Vaccine


  • Primrose Bio and Intravacc have entered into a strategic partnership to strengthen the development & supply of conjugate vaccines under which the third-party developers of conjugate vaccines gain access to a solution for vaccine conjugation, manufacturing, and supply
  • The collaboration will leverage Primrose Bio’s ultra-pure production, supply chain management & regulatory support for PeliCRM197, a component required for conjugate vaccine development
  • Intravacc will provide its technical knowledge, advanced facilities, expertise in antigen conjugation process development, scale-up & GMP production of conjugate vaccines to the collaboration

Ref: Intravacc | Image: Intravacc

Related News:- Merck’s Vaxneuvance (pneumococcal 15-valent conjugate vaccine) Receives the US FDA’s Approval for the Prevention of Invasive Pneumococcal Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions